2010
A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage
de Cabanyes Candela S, Detterbeck FC. A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage. Journal Of Thoracic Oncology 2010, 5: 389-398. PMID: 20186025, DOI: 10.1097/jto.0b013e3181ce3e5e.Peer-Reviewed Original ResearchConceptsInduction therapyPositron emission tomographyLung cancerComputed tomographySystematic reviewStage IIIA lung cancerEmission tomographyIIIA lung cancerMediastinal node involvementRepeat mediastinoscopyNode involvementComplete responsePathologic findingsEsophageal ultrasoundPathologic stageNeedle aspirationExpert handsRestagingFalse negative rateMediastinoscopyTherapyFN rateTomographyPatientsSurgery
2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA